Paul Fry, a former GlaxoSmithKline Plc executive, has been appointed a non-executive director of Avacta Group Plc, effective 3 February. He is currently chief financial officer of Vectura Group Plc, a drug delivery specialist. Prior to this, he was CFO at Immunocore Ltd, which is developing drugs based on T cell receptor technology. Avacta has technology for fighting cancer using a new type of drug conjugate.
Avacta Group announced the appointment on 21 January 2020.
Copyright 2020 Evernow Publishing Ltd